PHARMACY

New class of drugs could be used in treating Alzheimer’s

BY Alaric DeArment

SARASOTA, Fla. Researchers have detected a possible target for new treatments for Alzheimer’s disease.

The Roskamp Institute announced Tuesday that its researchers had found a link between the disease and inflammation and that this could lead to the development of new Alzheimer’s drugs. The study is published online in the American Chemical Society’s Chemical Biology Journal. 

Alzheimer’s disease is accompanied by inflammation, and abnormal deposits of the protein amyloid accumulate in the brains of those with the disease, often triggering inflammation. The inflammation is thought to eventually destroy nerve cells. 

The Roskamp researchers have found that inflammation can lead to the production of more amyloid, and they found that a receptor on the nerve cell surface called CXCR2 is an interface between inflammation and new amyloid production. As inflammatory molecules contact CXCR2, the contact generates a signal that results in increased amyloid production. In other words, the presence of amyloid contributes to its own reproduction. 

“[We] found that by genetically knocking out CXCR2, we can reduce the amount of amyloid in various laboratory models and, by using drugs that specifically block the CXCR2 receptor, we are able to show that a decrease in production of amyloid can be achieved,” Roskamp researcher Pancham Bakshi said in a statement. “This study, which for the first time shows the early role of inflammation in [Alzheimer’s disease], opens a new door for therapeutic intervention, potentially leading to the use of CXCR2 blocking agents as a way to treat both the inflammation and the amyloid production in Alzheimer’s disease.” 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Take Care opens three clinics in New Orleans area

BY Antoinette Alexander

CONSHOHOCKEN, Pa. Take Care Health Systems, which is owned by Walgreens, announced on Monday that it has opened three retail-based clinics in New Orleans, marking the first Take Care Clinics in the state of Louisiana.

Additional locations are slated to open in New Orleans in early 2009.

“We are excited to bring high-quality, affordable care to the citizens of New Orleans,” said Peter Miller, Take Care Health Systems’ president and chief executive officer. “We have watched this city overcome incredible obstacles in the past few years and we feel that its residents will greatly benefit from the increased access to health care offered by Take Care Clinics. Nearly one million patients have been treated at Take Care Clinics nationwide and we are proud to expand into New Orleans as part of our continued growth.”

Last year, Walgreens celebrated the opening of its 6,000th pharmacy location nationwide in New Orleans and has historically maintained a strong presence in the city.

Take Care Health Systems currently manages 312 clinics in 18 states.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Medicine Shoppe teams with ADA on American Diabetes Month activities

BY Alaric DeArment

NEW YORK A retail pharmacy chain and the American Diabetes Association are collaborating to mark American Diabetes Month with free cards listing healthy recipes for people with diabetes.

Medicine Shoppe will distribute the cards, partially funded by Bayer HealthCare, listing 10 recipes that the ADA has approved as safe for diabetics, including chicken, turkey, potato, sausage and vegetable dishes.

The cards, titled the “Live Health Nutritional Recipe Cards,” list nutrition information and serving sizes for each recipe.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?